Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 3/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.37 |
| ▸ | KIT | P10721 | 3/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482856 | 0.97 | ALOX5AP (0.42) | ALOX5APCYP11B1CYP11B2CHEK1FYN | |
| Bromide SCHEMBL1483324 | 0.96 | ALOX5AP (0.41) | ALOX5APCYP11B1CYP11B2CHEK1FYN | |
| SCHEMBL2678254 | 0.92 | ALOX5AP (0.43) | ALOX5APCYP11B1CYP11B2CHEK1FYN | |
| Hydrochloric Acid SCHEMBL2678766 | 0.91 | ALOX5AP (0.42) | ALOX5APCYP11B1CYP11B2CHEK1FYN | |
| Fumaric Acid SCHEMBL4263917 | 0.88 | CSF1R (0.39) | ALOX5APCHEK1CSF1RPDGFRBKIT | |
| SCHEMBL1483242 | 0.84 | NAMPT (0.42) | ALOX5APPIM1 | |
| SCHEMBL2678244 | 0.81 | HSD11B1 (0.41) | CYP11B1CYP11B2 | |
| SCHEMBL1482857 | 0.81 | ALOX5AP (0.38) | ALOX5APPIM1MAPK1 | |
| SCHEMBL2679668 | 0.80 | ALOX5AP (0.39) | ALOX5APCYP11B1CYP11B2CHEK1 | |
| SCHEMBL2679498 | 0.80 | ALOX5AP (0.41) | ALOX5APCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759343-B2 | Azabicycloalkane derivatives, preparation thereof and use thereof in therapy | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| EP-2118104-B1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI SA (FR) | 2013-01-02 | — | — | EP | disclosed |
| US-20120202807-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI (FR) | 2012-08-09 | — | — | US | disclosed |
| US-8173669-B2 | Azabicycloalkane derivatives, preparation thereof and use thereof in therapy | SANOFI-AVENTIS (FR) | 2012-05-08 | — | — | US | disclosed |
| US-20100035916-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2118104-A2 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | Sanofi-Aventis (FR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008110699-A2 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202807-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | TPMT, CYP51A1, ABL1 | ALOX5AP 666/4885CYP11B1 24/4885CYP11B2 29/4885 |
| US-20100035916-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | TPMT, CYP51A1, ABL1 | ALOX5AP 666/4885CYP11B1 24/4885CYP11B2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.